Zydus Lifesciences Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
1004.00 +3.50 (0.35%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
997.9
Today’s High
1010.55
52 Week Low
567.85
52 Week High
1323.9
1005.70 +4.70 (0.47%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
996.95
Today’s High
1010.15
52 Week Low
567.75
52 Week High
1324.3
Key Metrics
- Market Cap (In Cr) 100724
- Beta 0.39
- Div. Yield (%) 0.3
- P/B 5.08
- TTM P/E 26
- Peg Ratio 2.31
- Sector P/E 33.71
- D/E -
- Open Price 1010.55
- Prev Close 1000.5
Zydus Lifesciences Analysis
Price Analysis
-
1 Week-1.87%
-
3 Months-15.13%
-
6 Month7.23%
-
YTD45.24%
-
1 Year75.51%
Risk Meter
- 30% Low risk
- 30% Moderate risk
- 30% Balanced Risk
- 30% High risk
- 30% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 3
- 3
- Buy
- 5
- 5
- 5
- 5
- Hold
- 10
- 10
- 10
- 10
- Sell
- 6
- 6
- 5
- 4
- Strong Sell
- 3
- 3
- 3
- 3
- Total
- 27
- 27
- 26
- 25
Zydus Lifesciences News
Buy or sell: Vaishali Parekh recommends three stocks to buy today — Oct 24
1 min read . 08:41 AM ISTStocks to Watch: TCS, Tata Elxsi, IREDA, Mazagon Dock, Zydus Life, RIL, and more
2 min read . 11 Oct 2024Stocks to Watch: Mankind Pharma, Suzlon, Adani Ent, Godrej Properties, and more
4 min read . 03 Oct 2024Stocks to Watch: IDFC First Bank, PNB, Dr Reddy's, REC, RIL, Welspun and more
2 min read . 30 Sep 2024Zydus Lifesciences Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 19547.4
- Selling/ General/ Admin Expenses Total
- 3137.6
- Depreciation/ Amortization
- 764.1
- Other Operating Expenses Total
- 4878.3
- Total Operating Expense
- 15022.4
- Operating Income
- 4525
- Net Income Before Taxes
- 4808.9
- Net Income
- 3859.5
- Diluted Normalized EPS
- 38.02
- Period
- 2024
- Total Assets
- 29280.8
- Total Liabilities
- 9451.3
- Total Equity
- 19829.5
- Tangible Book Valueper Share Common Eq
- 118.81
- Period
- 2024
- Cashfrom Operating Activities
- 3233.9
- Cashfrom Investing Activities
- -1475.2
- Cashfrom Financing Activities
- -1810.4
- Net Changein Cash
- -74.8
- Period
- 2023
- Total Revenue
- 17237.4
- Selling/ General/ Admin Expenses Total
- 6263.3
- Depreciation/ Amortization
- 722.7
- Other Operating Expenses Total
- 342.3
- Total Operating Expense
- 14988.8
- Operating Income
- 2248.6
- Net Income Before Taxes
- 2589.7
- Net Income
- 1960.3
- Diluted Normalized EPS
- 23.79
- Period
- 2023
- Total Assets
- 25756.4
- Total Liabilities
- 8240.6
- Total Equity
- 17515.8
- Tangible Book Valueper Share Common Eq
- 114.81
- Period
- 2023
- Cashfrom Operating Activities
- 2688.8
- Cashfrom Investing Activities
- 1171.2
- Cashfrom Financing Activities
- -4400.4
- Net Changein Cash
- -533.8
- Period
- 2022
- Total Revenue
- 15109.9
- Selling/ General/ Admin Expenses Total
- 5385.9
- Depreciation/ Amortization
- 713
- Other Operating Expenses Total
- 288.4
- Total Operating Expense
- 12523.1
- Operating Income
- 2586.8
- Net Income Before Taxes
- 2838.1
- Net Income
- 4487.3
- Diluted Normalized EPS
- 21.01
- Period
- 2022
- Total Assets
- 27795.4
- Total Liabilities
- 10795.8
- Total Equity
- 16999.6
- Tangible Book Valueper Share Common Eq
- 102.64
- Period
- 2022
- Cashfrom Operating Activities
- 2078.2
- Cashfrom Investing Activities
- 1154.4
- Cashfrom Financing Activities
- -868.3
- Net Changein Cash
- 2372.9
- Period
- 2021
- Total Revenue
- 14403.5
- Selling/ General/ Admin Expenses Total
- 5254.6
- Depreciation/ Amortization
- 669.6
- Other Operating Expenses Total
- 301
- Total Operating Expense
- 11873
- Operating Income
- 2530.5
- Net Income Before Taxes
- 2399.2
- Net Income
- 2133.6
- Diluted Normalized EPS
- 23.38
- Period
- 2021
- Total Assets
- 23884.7
- Total Liabilities
- 10892.4
- Total Equity
- 12992.3
- Tangible Book Valueper Share Common Eq
- 62.61
- Period
- 2021
- Cashfrom Operating Activities
- 3185.1
- Cashfrom Investing Activities
- -722.5
- Cashfrom Financing Activities
- -2548.9
- Net Changein Cash
- -90.5
- Period
- 2020
- Total Revenue
- 14253.1
- Selling/ General/ Admin Expenses Total
- 5142.8
- Depreciation/ Amortization
- 696.5
- Other Operating Expenses Total
- 804.3
- Total Operating Expense
- 12515.1
- Operating Income
- 1738
- Net Income Before Taxes
- 1495.4
- Net Income
- 1176.6
- Diluted Normalized EPS
- 14.4
- Period
- 2020
- Total Assets
- 23686.6
- Total Liabilities
- 13310.9
- Total Equity
- 10375.7
- Tangible Book Valueper Share Common Eq
- 35.14
- Period
- 2020
- Cashfrom Operating Activities
- 2505.4
- Cashfrom Investing Activities
- -1012.3
- Cashfrom Financing Activities
- -1094.2
- Net Changein Cash
- 398.9
- Period
- 2019
- Total Revenue
- 13165.6
- Selling/ General/ Admin Expenses Total
- 4287.6
- Depreciation/ Amortization
- 598.6
- Other Operating Expenses Total
- 592.2
- Total Operating Expense
- 10783.4
- Operating Income
- 2382.2
- Net Income Before Taxes
- 2382.1
- Net Income
- 1848.8
- Diluted Normalized EPS
- 18.12
- Period
- 2019
- Total Assets
- 23483.1
- Total Liabilities
- 13096.8
- Total Equity
- 10386.3
- Tangible Book Valueper Share Common Eq
- 32.51
- Period
- 2019
- Cashfrom Operating Activities
- 1543.2
- Cashfrom Investing Activities
- -4238.7
- Cashfrom Financing Activities
- 1884.6
- Net Changein Cash
- -810.9
- Period
- 2018
- Total Revenue
- 11954.4
- Selling/ General/ Admin Expenses Total
- 3850
- Depreciation/ Amortization
- 538.8
- Other Operating Expenses Total
- 467
- Total Operating Expense
- 9643.4
- Operating Income
- 2311
- Net Income Before Taxes
- 2330.8
- Net Income
- 1775.8
- Diluted Normalized EPS
- 17.65
- Period
- 2018
- Total Assets
- 18065.3
- Total Liabilities
- 9320.8
- Total Equity
- 8744.5
- Tangible Book Valueper Share Common Eq
- 59.37
- Period
- 2018
- Cashfrom Operating Activities
- 919.3
- Cashfrom Investing Activities
- -973.7
- Cashfrom Financing Activities
- 51.5
- Net Changein Cash
- -2.9
- Period
- 2024-06-30
- Total Revenue
- 6207.5
- Selling/ General/ Admin Expenses Total
- 883.5
- Depreciation/ Amortization
- 215.3
- Other Operating Expenses Total
- 1628.7
- Total Operating Expense
- 4313.6
- Operating Income
- 1893.9
- Net Income Before Taxes
- 1899.7
- Net Income
- 1419.9
- Diluted Normalized EPS
- 14.11
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 5533.8
- Selling/ General/ Admin Expenses Total
- 837
- Depreciation/ Amortization
- 205.3
- Other Operating Expenses Total
- 1460.1
- Total Operating Expense
- 4113.9
- Operating Income
- 1419.9
- Net Income Before Taxes
- 1547
- Net Income
- 1182.3
- Diluted Normalized EPS
- 11.66
- Period
- 2024-03-31
- Total Assets
- 29280.8
- Total Liabilities
- 9451.3
- Total Equity
- 19829.5
- Tangible Book Valueper Share Common Eq
- 118.81
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 3233.9
- Cashfrom Investing Activities
- -1475.2
- Cashfrom Financing Activities
- -1810.4
- Net Changein Cash
- -74.8
- Period
- 2023-12-31
- Total Revenue
- 4505.2
- Selling/ General/ Admin Expenses Total
- 817.3
- Depreciation/ Amortization
- 194.8
- Other Operating Expenses Total
- 1137.6
- Total Operating Expense
- 3618.2
- Operating Income
- 887
- Net Income Before Taxes
- 925.5
- Net Income
- 789.6
- Diluted Normalized EPS
- 7.58
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 4368.8
- Selling/ General/ Admin Expenses Total
- 752.9
- Depreciation/ Amortization
- 184.2
- Other Operating Expenses Total
- 1078.2
- Total Operating Expense
- 3489.1
- Operating Income
- 879.7
- Net Income Before Taxes
- 1007.2
- Net Income
- 800.7
- Diluted Normalized EPS
- 7.92
- Period
- 2023-09-30
- Total Assets
- 25879.4
- Total Liabilities
- 7146.6
- Total Equity
- 18732.8
- Tangible Book Valueper Share Common Eq
- 127.21
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 2212.9
- Cashfrom Investing Activities
- -709.3
- Cashfrom Financing Activities
- -1645.1
- Net Changein Cash
- -141.5
- Period
- 2023-06-30
- Total Revenue
- 5139.6
- Selling/ General/ Admin Expenses Total
- 730.4
- Depreciation/ Amortization
- 179.8
- Other Operating Expenses Total
- 1202.4
- Total Operating Expense
- 3801.2
- Operating Income
- 1338.4
- Net Income Before Taxes
- 1329.2
- Net Income
- 1086.9
- Diluted Normalized EPS
- 10.87
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 4667.7
- Selling/ General/ Admin Expenses Total
- 723.9
- Depreciation/ Amortization
- 178.6
- Other Operating Expenses Total
- 1276.6
- Total Operating Expense
- 4476.4
- Operating Income
- 191.3
- Net Income Before Taxes
- 485.8
- Net Income
- 296.6
- Diluted Normalized EPS
- 7.22
- Period
- 2023-03-31
- Total Assets
- 25756.4
- Total Liabilities
- 8240.6
- Total Equity
- 17515.8
- Tangible Book Valueper Share Common Eq
- 114.81
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 2688.8
- Cashfrom Investing Activities
- 1171.2
- Cashfrom Financing Activities
- -4400.4
- Net Changein Cash
- -533.8
- Period
- 2022-12-31
- Total Revenue
- 4362.3
- Selling/ General/ Admin Expenses Total
- 689
- Depreciation/ Amortization
- 181.6
- Other Operating Expenses Total
- 1206.9
- Total Operating Expense
- 3587.9
- Operating Income
- 774.4
- Net Income Before Taxes
- 780.1
- Net Income
- 622.9
- Diluted Normalized EPS
- 6.15
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Zydus Lifesciences Technical
Moving Average
SMA
- 5 Day1011.12
- 10 Day1036.38
- 20 Day1050.1
- 50 Day1107.65
- 100 Day1117.23
- 300 Day1006.91
Zydus Lifesciences Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Torrent Pharmaceuticals
- 3316
- -5.1
- -0.15
- 3589.95
- 1822.8
- 112233.34
- Dr Reddys Laboratories
- 6589.2
- -17.15
- -0.26
- 7101
- 5212.1
- 109728.95
- Zydus Lifesciences
- 1004
- 3.5
- 0.35
- 1323.9
- 567.85
- 101002.4
- Lupin
- 889.05
- 8.25
- 0.94
- 889.9
- 602.8
- 40512.13
- Alkem Laboratories
- 5935.95
- 74.25
- 1.27
- 6440
- 3509.6
- 70964.28
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Torrent Pharmaceuticals
- 71.61
- 16.75
- 20.64
- 13.18
- Dr Reddys Laboratories
- 20.27
- 3.95
- 16.73
- 14.63
- Zydus Lifesciences
- 26.52
- 5.1
- 15.65
- 14.33
- Lupin
- 47.43
- 6.86
- 2.51
- 2.04
- Alkem Laboratories
- 40.94
- 7.14
- 18.26
- 13.94
Zydus Lifesciences Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 09-Aug-24
- Quarterly Results
- 17-May-24
- Audited Results & Final Dividend
- 09-Feb-24
- Quarterly Results & Buy Back of shares
- 07-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 18-May-23
- Audited Results & Final Dividend
- 03-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 10-Aug-22
- Quarterly Results
- 20-May-22
- Audited Results, Dividend & Buy Back
- Meeting Date
- Announced on
- Purpose
- 09-Aug-24
- 17-May-24
- AGM
- 11-Aug-23
- 18-May-23
- AGM
- 10-Aug-22
- 21-May-22
- AGM
- 18-Feb-22
- 25-Jan-22
- EGM
- 11-Aug-21
- 27-May-21
- AGM
- 11-Jun-21
- 18-May-21
- EGM
- -
- 20-May-22
- Others
- -
- 12-Feb-24
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 17-May-24
- 26-Jul-24
- 26-Jul-24
- 3
- 18-May-23
- 28-Jul-23
- 28-Jul-23
- 6
- 20-May-22
- 29-Jul-22
- 28-Jul-22
- 2.5
- 27-May-21
- -
- 28-Jul-21
- 3.5